Abstract
Objectives
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Value in HealthReferences
- A health economics approach to US value assessment frameworks-introduction: an ISPOR Special Task Force report [1].Value Health. 2018; 21: 119-123
- A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR Special Task Force report [7].Value Health. 2018; 21: 161-165
- Second Panel on Cost-Effectiveness in Health and Medicine.Oxford University Press, Oxford, United Kingdom2016
- An overview of value, perspective, and decision context—a health economics approach: an ISPOR Special Task Force report [2].Value Health. 2018; 21: 124-130
- Linking pharmacogenetics-based diagnostics and drugs for personalized medicine.Health Aff (Millwood). 2006; 25: 1281-1290
- The economics of personalized medicine: a model of incentives for value creation and capture.Drug Inf J. 2007; 41: 501-509
- Knowing for the sake of knowing: the value of prognostic information.Med Decis Making. 1990; 10: 47-57
- Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.Health Econ. 2012; 21: 238-251
- The value of knowing and knowing the value: improving the health technology assessment of complementary diagnostics. Office of Health Economics, EPEMED.(Accessed March 4, 2022)
- Economic foundations of cost-effectiveness analysis.J Health Econ. 1997; 16: 1-31
- Real option value and path dependence in oncology innovation.Int J Econ Bus. 2011; 18: 225-238
- How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies.Health Aff (Millwood). 2012; 31: 676-682
- The insurance value of medical innovation.J Public Econ. 2017; 145: 94-102
- Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis.Value Health. 2017; 20: 213-216
- Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3].Value Health. 2018; 21: 131-139
- Can and should value-based pricing be applied to molecular diagnostics?.Pers Med. 2013; 10: 61-72
Garau M, Towse A. Assessment of Co-Dependent Technologies. Presentation in Issues Panel “How Do You Assess the Value of Codependent Technologies?” ISPOR, Office of Health Economics. https://www.slideshare.net/OHENews/implications-of-codependent-technologies-in-medicine. Accessed March 4, 2022.
- Review of recent US value frameworks—a health economics approach: an ISPOR Special Task Force report [6].Value Health. 2018; 21: 155-160
- The Right Price: A Value-Based Prescription for Drug Costs.Oxford University Press, Oxford, United Kingdom2021
- Value Based Pricing in Sweden: Lessons for Design? Office of Health Economics.(Accessed March 4, 2022)
- SMC modifiers used in appraising new medicines. Scottish Medicines Consortium.https://www.scottishmedicines.org.uk/media/3565/modifiers.pdfDate accessed: December 20, 2021
- CHTE methods review. Modifiers: Task and finish group report. National Institute for Health and Care Excellence.(Accessed March 4, 2022)
NICE health technology evaluations: the draft manual. https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/nice-guidance/chte-methods-and-processes-consultation/health-technology-evaluations-manual.docx. Accessed October 1, 2021.
- ICER value framework 2020 update: recommendations on the aggregation of benefits and contextual considerations.Value Health. 2020; 23: 1040-1048
Watkins JB, Tsiao E, Premera Blue Cross, Pharmacy and Therapeutics Committee, 2019.
- New approaches to value assessment: towards more informed pricing in healthcare—an introduction.Value Health. 2019; 22: S1-S3
- Novel approaches to value assessment beyond the cost-effectiveness framework.Value Health Reg Issues. 2019; 22: S18-S23
- Health technology assessment with risk aversion in health [published correction appears in J Health Econ. 2021;78:102474].J Health Econ. 2020; 72102346
- Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach.Value Health. 2021; 24: 244-249
Lakdawalla DN, Phelps CE. A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE) [published online September 8, 2021]. Eur J Health Econ. https://doi.org/10.1007/s10198-021-01367-0.
Phelps CE, Lakdawalla DN. The generalized and risk-adjusted cost effectiveness (GRACE) methodology: overview and implementation. Oxford, United Kingdom: Oxford University Press; Forthcoming.
- Quality-adjusted life years and the devaluation of life with disability. National Council on Disability.(Accessed March 4, 2022)
- Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents.Expert Rev Pharmacoecon Outcomes Res. 2013; 13: 513-522
- 2020-2023 value assessment framework. Institute for Clinical and Economic Review.(Accessed March 4, 2022)
- Novel elements of the value flower: fake or truly novel? Value Outcomes Spotlight ISPOR.(Accessed March 4, 2022)
- Patient variability seldom assessed in cost-effectiveness studies.Med Decis Making. 2018; 38: 487-494
- Extended cost-effectiveness analysis for health policy assessment: a tutorial.Pharmacoeconomics. 2016; 34: 913-923
- Using cost-effectiveness analysis to address health equity concerns.Value Health. 2017; 20: 206-212
- Distributional Cost-Effectiveness Analysis. Quantifying Health Equity Impacts and Trade-Offs.Oxford University Press, Oxford, United Kingdom2020
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. In press.
- Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications.Value Health. 2022; 25: 59-68
- Augmenting cost-effectiveness analysis for uncertainty: the implications for value assessment-rationale and empirical support.J Manag Care Spec Pharm. 2020; 26: 400-406
- Measuring the value healthy individuals place on generous insurance coverage of severe diseases: a stated preference survey of adults diagnosed with and without lung cancer.Value Health. 2021; 24: 855-861
- Measuring “fearonomic effects” in valuing therapies: an application to COVID-19 in China.Value Health. 2020; 23: 1405-1408
- Patient versus physician valuation of durable survival gains: implications for value framework assessments.Value Health. 2017; 20: 217-223
- Quantifying value of hope.Value Health. 2021; 24: 1511-1519
- The option value of Innovation.Forum Health Econ Policy. 2012; 1520122005
- Do cancer treatments have option value? Real-world evidence from metastatic melanoma.Health Econ. 2019; 28: 855-867
- How does option value affect the potential cost-effectiveness of a treatment? The case of ipilimumab for metastatic melanoma.Value Health. 2019; 22: 777-784
- Broadening the concept of value: a scoping review on the option value of medical technologies.Value Health. 2021; 24: 1045-1058
- The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.Am J Manag Care. 2017; 23: e340-e346
- The option value of innovative treatments for metastatic melanoma.Forum Health Econ Policy. 2018; 2120160014
- Real-world evidence for option value in metastatic melanoma.J Manag Care Spec Pharm. 2021; 27: 1546-1555
- Modeling the ex post real option value in metastatic melanoma using real-world data.Value Health. 2021; 24: 1746-1753
- Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold.J Manag Care Spec Pharm. 2019; 25: 793-799
- An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does it make a difference?.Health Policy. 2018; 122: 607-613
- The impact of social and novel elements on cost-effectiveness analysis: two case studies.Value Health. 2021; 24: S147
- How excluding some benefits from value assessment of new drugs impacts innovation.Health Econ. 2017; 26: 1813-1825
- Perspective and costing in cost-effectiveness analysis, 1974-2018.Pharmacoeconomics. 2020; 38: 1135-1145
- Patient adherence: a blind spot in cost-effectiveness analyses?.Am J Manag Care. 2009; 15: 626-632
- Expanding the scope of costs and benefits for economic evaluations in health: some words of caution.Pharmacoeconomics. 2019; 37: 457-460
- Health technology assessment in the U.S.—a vision for the future. USC Schaeffer Center.(Accessed March 4, 2022)